Pepaxto
FDA Issues Final Decision to Withdraw Approval of Pepaxto for Multiple Myeloma
The FDA has announced its final decision to withdraw approval of melphalan flufenamide (Pepaxto, Oncopeptides), ...
FEBRUARY 26, 2024
Oncopeptides Withdraws Pepaxto From U.S. Market Based on OCEAN Results
Oncopeptides AB has withdrawn melphalan flufenamide (Pepaxto) from the market in the United States, after results ...
OCTOBER 28, 2021
FDA Issues Warning About Pepaxto
The FDA issued an alert notifying patients and health care professionals that a clinical trial in patients ...
AUGUST 9, 2021
FDA Approves Pepaxto for Triple-Refractory Multiple Myeloma
The FDA granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with ...
MARCH 5, 2021
Load more